This study underscores NAT10’s pivotal role in modulating the prostate cancer immune microenvironment, offering insights into the immune desert phenomenon and identifying NAT10 as a promising therapeutic target for improving immunotherapy efficacy. The gene discussed is NAT10; the disease is Familial prostate cancer.